Many stocks have been testing new highs in 2020, and one of the most notable is CRISPR Therapeutics AG (CRSP). Currently, CRSP is trading at $63.26 and the avg recommendation for the stock is Moderate Buy. while the current analyst price target stands at $75.19.
To add more color to this target, the company’s high over the last year is $74.00 and the low is $32.30. Over the last 52 weeks, CRSP is down -14.51% while the S&P 500 is down -0.75%. The catalyst for this interesting swing was the company’s recent earnings report.
A Notable Earnings Report
In the last quarter, CRSP reported a profit of $73.74 million. CRISPR Therapeutics AG also saw revenues increase to $0.16 million. In addition, CRSP has free cash flow of -$55.17 million as of 03-2020 The company’s EBITDA came in at -$71.5 million which compares well with its peers.
CRSP booked profit margins of 15.70%, its Return on Equity (ROE) is 6.50%, and its Return on Assets is 5.50%. All told, it is clear that, CRSP needs to be on your watchlist.
Find out when CRSP reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
Of course, we must look beyond the financials and question how well those numbers represent the sustainable earnings power of the business. Investors need to know how sustainable this current run. CRSP has a short ratio of 4.57 and outstanding shares of 60.85M.
CRSP has seen increased volume after this news and investors are putting their support behind the value proposition. Furthermore, 10-day volume stands at 0.77 million and more growth is possible in the weeks ahead. Traders will also note the company’s earnings per share came in at 0.75. CRISPR Therapeutics AG CRSP also noted assets of $1.01 billion at the end of the last quarter. Investors should also keep an eye on sector updates as CRSP has historically followed its peers on positive news.
All told, CRISPR Therapeutics AG CRSP has strung together solid data and demonstrated underlying fundamentals. At its current valuation, CRSP represents an interesting risk/reward case. Traders should stay tuned to see if this recent report will push the stock to test recent resistance levels.
CRISPR Therapeutics AG CRSP is now commanding a market cap of 3.95B and a float of 51.14M. CRSP is increasing its credibility in this sector and that could lead to more upside down the line. Sign-up for continuing coverage on shares of CRSP stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in CRSP, either long or short, and we have not been compensated for this article.